SLDB Stock Price, Solid Biosciences Inc Quote, Chart

Market Summary

USD8.52-0.25

Market Closed

-2.85%

SLDB Stock Price

View Fullscreen

SLDB RSI Chart

SLDB Valuation

Market Cap

321.7M

Price/Earnings (Trailing)

-3.35

Price/Sales (Trailing)

56.96

Price/Free Cashflow

-3.36

SLDB Price/Sales (Trailing)

SLDB Profitability

Return on Equity

-75.91%

Return on Assets

-58.21%

Free Cashflow Yield

-29.75%

SLDB Fundamentals

SLDB Revenue

Revenue (TTM)

8.1M

SLDB Earnings

Earnings (TTM)

-96.0M

Earnings Growth (Yr)

-34.22%

Earnings Growth (Qtr)

3.07%

Breaking Down SLDB Revenue

Last 7 days

-8.0%

Last 30 days

-37.2%

Last 90 days

6.8%

Trailing 12 Months

81.3%

How does SLDB drawdown profile look like?

SLDB Financial Health

Current Ratio

8.94

SLDB Investor Care

Shares Dilution (1Y)

167.79%

Diluted EPS (TTM)

-4.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	12.2M	14.8M	11.2M	8.1M
2021	0	0	0	13.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Solid Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	smith ian f	acquired	-	-	3,256	-
Jan 29, 2024	ganot ilan	sold	-1,110	7.99	-139	-
Jan 27, 2024	ganot ilan	acquired	-	-	388	-
Jan 27, 2024	ganot ilan	acquired	-	-	3,883	-
Jan 11, 2024	perceptive advisors llc	bought	18,861,200	5.53	3,410,710	-
Jan 11, 2024	koppel adam	acquired	5,000,000	5.53	904,160	-
Jan 11, 2024	ra capital management, l.p.	bought	5,000,000	5.53	904,160	-
Jan 11, 2024	bain capital life sciences investors, llc	acquired	5,000,000	5.53	904,160	-
Jan 09, 2024	tan kevin	acquired	-	-	11,250	cfo & treasurer
Jan 09, 2024	tan kevin	sold	-32,267	8.2	-3,935	cfo & treasurer

Which funds bought or sold SLDB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	new	-	176,610	176,610	-%
Mar 11, 2024	VANGUARD GROUP INC	added	29.64	1,360,260	1,990,410	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	12,655,300	21,465,000	0.48%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	16,000	27,000	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	reduced	-1.44	2,283,450	3,912,890	0.03%
Feb 14, 2024	Royal Bank of Canada	added	20.09	12,000	18,000	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	41.6	222,626	313,490	0.01%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	228,396	228,396	-%
Feb 14, 2024	LAZARD ASSET MANAGEMENT LLC	sold off	-100	-5,000	-	-%

Are Funds Buying or Selling SLDB?

Are funds buying SLDB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLDB

No. of Funds

Unveiling Solid Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	adage capital partners gp, l.l.c.	7.25%	2,712,478	SC 13G
Jan 22, 2024	artal international s.c.a.	7.3%	2,717,538	SC 13G
Jan 12, 2024	flynn james e	6.08%	2,260,398	SC 13G
Jan 12, 2024	perceptive advisors llc	18.6%	6,925,028	SC 13D/A
Jan 12, 2024	bcls sb investco, lp	1.4%	528,660	SC 13D/A
Jan 11, 2024	ra capital management, l.p.	11.7%	4,348,828	SC 13D/A
Jan 10, 2024	bcls sb investco, lp	2.6%	528,660	SC 13D/A
Feb 13, 2023	suvretta capital management, llc	0%	0	SC 13G/A
Feb 13, 2023	k2 principal fund, l.p.	1.46%	284,871	SC 13G/A
Feb 10, 2023	ecor1 capital, llc	0%	0	SC 13G/A

Recent SEC filings of Solid Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Apr 05, 2024	4	Insider Trading
Mar 13, 2024	10-K	Annual Report
Mar 13, 2024	S-3	S-3
Mar 13, 2024	S-8	Employee Benefits Plan
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading

Peers (Alternatives to Solid Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Solid Biosciences Inc News

Latest updates

Solid Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-	-	-	6.00	2.00	3.00	4.00	4.00	3.00
Operating Expenses	63.6%	35.00	21.00	32.00	27.00	22.00	22.00	22.00	20.00
S&GA Expenses	6.9%	8.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00
R&D Expenses	52.0%	21.00	14.00	23.00	20.00	15.00	14.00	16.00	14.00
Net Income	25.8%	-15.15	-20.41	-25.09	-25.33	-18.61	-17.98	-18.69	-16.90
Net Income Margin	-33.6%	-10.62*	-7.95*	-5.89*	-6.60*	-5.30*	-	-	-
Free Cashflow	-66.1%	-35.34	-21.27	-17.01	-27.37	-21.53	-18.66	-17.45	-21.40

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.7%	165	185	205	230	260	184	208	208	232	249	266	285	171	41.00	58.00	74.00	103	131	96.00	120	140
Current Assets	-12.5%	130	148	167	191	220	148	170	199	223	239	255	274	159	27.00	44.00	58.00	86.00	113	78.00	102	129
Cash Equivalents	50.9%	74.00	49.00	92.00	165	155	49.00	54.00	130	119	110	201	268	155	25.00	41.00	54.00	76.00	95.00	52.00	54.00	86.00
Net PPE	-6.0%	7.00	7.00	7.00	9.00	10.00	6.00	7.00	6.00	6.00	7.00	7.00	7.00	8.00	9.00	10.00	11.00	12.00	11.00	12.00	12.00	10.00
Liabilities	-4.7%	38.00	40.00	41.00	46.00	49.00	41.00	46.00	22.00	24.00	26.00	28.00	32.00	39.00	18.00	17.00	18.00	23.00	22.00	20.00	21.00	14.00
Current Liabilities	-8.2%	15.00	16.00	16.00	20.00	23.00	17.00	22.00	22.00	24.00	23.00	23.00	23.00	24.00	15.00	13.00	13.00	18.00	17.00	14.00	15.00	12.00
Shareholder's Equity	-12.4%	126	144	164	184	212	143	162	186	208	223	238	253	132	22.00	41.00	56.00	80.00	109	76.00	99.00	125
Retained Earnings	-3.2%	-658	-638	-617	-592	-562	-547	-527	-502	-476	-458	-440	-421	-404	-383	-361	-342	-316	-284	-255	-228	-199
Additional Paid-In Capital	0.3%	785	783	781	777	774	691	689	688	685	681	678	674	537	405	403	399	396	393	332	328	324
Shares Outstanding	1.6%	20.00	20.00	20.00	20.00	20.00	8.00	8.00	8.00	7.00	7.00	7.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	52.00	-	-	-	46.00	-	-	-	272	-	-	-	73.00	-	-	-	101	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-16.3%	-20,823	-17,897	-27,465	-27,995	-34,480	-20,429	-15,878	-27,190	-20,874	-18,424	-17,100	-21,366	1,307	-15,564	-13,068	-29,274	-21,245	-19,241	-26,301	-25,927	-21,404
Share Based Compensation	19.3%	1,938	1,625	1,944	2,118	1,587	1,524	1,814	2,612	3,415	3,416	3,635	2,907	2,518	2,764	3,243	3,104	3,404	3,392	3,911	3,500	2,030
Cashflow From Investing	283.9%	45,296	-24,635	-48,232	37,260	66,100	14,909	-59,595	37,743	30,176	-72,510	-48,717	-35.00	-60.00	-80.00	322	6,418	2,855	3,963	24,143	-6,445	-21,264
Cashflow From Financing	-	505	-	-	-	74,737	-1.00	73.00	22.00	66.00	3.00	-238	135,154	-	-	-	-	-287	-	-	-	-13.00

SLDB Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 76,563	$ 78,420	$ 58,739
General and administrative	27,752	28,948	27,135
Restructuring expense	(63)	7,178
Total operating expenses	104,252	114,546	85,874
Loss from operations	(104,252)	(106,452)	(72,254)
Other income, net:
Interest income, net	7,142	2,616	64
Gain on acquisition		18,236
Other income (expense)	1,095	(381)	2
Total other income, net	8,237	20,471	66
Net loss	$ (96,015)	$ (85,981)	$ (72,188)
Net loss per share, basic	$ (4.83)	$ (10.1)	$ (10.14)
Net loss per share, diluted	$ (4.83)	$ (10.1)	$ (10.14)
Weighted average common stock outstanding basic	19,884,007	8,512,089	7,118,024
Weighted average common stock outstanding, diluted	19,884,007	8,512,089	7,118,024
Related Party [Member]
Collaboration revenue - related party		$ 8,094	$ 13,620

SLDB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 74,015	$ 155,384
Available-for-sale securities	49,625	58,338
Prepaid expenses and other current assets	6,094	5,916
Total current assets	129,734	219,638
Operating lease, right-of-use asset	26,539	28,949
Property and equipment, net	6,624	9,657
Other non-current assets	209	175
Restricted cash	1,833	1,833
Total assets	164,939	260,252
Current liabilities:
Accounts payable	2,032	3,238
Accrued expenses	10,137	16,691
Operating lease liabilities	1,855	1,897
Finance lease liabilities	469	668
Other current liabilities	24	14
Total current liabilities	14,517	22,508
Operating lease liabilities, excluding current portion	22,707	24,279
Finance lease obligations, excluding current portion	1,234	1,703
Other non-current liabilities		96
Total liabilities	38,458	48,586
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022; no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.001 par value; 60,000,000 shares authorized at December 31, 2023 and December 31, 2022; 20,386,606 shares issued and outstanding at December 31, 2023 and 19,556,732 shares issued and outstanding at December 31, 2022	20	20
Additional paid-in capital	785,199	774,452
Accumulated other comprehensive income (loss)	15	(68)
Accumulated deficit	(658,753)	(562,738)
Total stockholders' equity	126,481	211,666
Total liabilities and stockholders' equity	$ 164,939	$ 260,252

About Solid Biosciences Inc

Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

CEO	Mr. Alexander G. Cumbo
WEBSITE	solidbio.com
INDUSTRY	Biotechnology
EMPLOYEES	87

Solid Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Solid Biosciences Inc? What does SLDB stand for in stocks?

SLDB is the stock ticker symbol of Solid Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Solid Biosciences Inc (SLDB)?

As of Thu Apr 25 2024, market cap of Solid Biosciences Inc is 321.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLDB stock?

You can check SLDB's fair value in chart for subscribers.

What is the fair value of SLDB stock?

You can check SLDB's fair value in chart for subscribers. The fair value of Solid Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Solid Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLDB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Solid Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SLDB is over valued or under valued. Whether Solid Biosciences Inc is cheap or expensive depends on the assumptions which impact Solid Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLDB.

What is Solid Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, SLDB's PE ratio (Price to Earnings) is -3.35 and Price to Sales (PS) ratio is 56.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLDB PE ratio will change depending on the future growth rate expectations of investors.